Ascendis Pharma A/S
Open
$228.31
Prev. Close
$228.45
High
$228.31
Low
$227.90
Market Snapshot
$13.46B
-50.4
-7.09
$388.36M
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
emptyResult
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Recently from Cashu
Ascendis Pharma's Yuviwel Approved: Pioneering Treatment for Children's Achondroplasia
Regulatory Success: Yuviwel Approval Marks a Major Milestone for Ascendis Pharma Ascendis Pharma A/S achieves a significant milestone with the recent approval of Yuviwel (navepegritide) by the U.S. Fo…
Ascendis Pharma's Yuviwel Approved by FDA, Advancing Pediatric Care for Achondroplasia
Ascendis Pharma Secures FDA Approval for Yuviwel, Advancing Pediatric Care for Achondroplasia Ascendis Pharma A/S achieves a significant milestone with the recent U.S. Food and Drug Administration (FD…
FDA Approves Yuviwel: A Game-Changer for Pediatric Achondroplasia Treatment by Ascendis Pharma
Yuviwel’s FDA Approval Marks a Milestone for Ascendis Pharma in Pediatric Treatment Ascendis Pharma A/S achieves a significant breakthrough with the recent approval from the U.S. Food and Drug Adminis…
Ascendis Pharma A/S Sees 10.27% Surge in Short Interest, Signaling Investor Concerns
Ascendis Pharma's Short Interest Surge: Implications for the Biotech Sector Ascendis Pharma A/S, a biotechnology company focused on innovative treatments, faces a significant rise in short interest, w…